Metastatic Breast Cancer - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 966
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MB3A6A9FA2FEN
Leaflet:

Download PDF Leaflet

Metastatic Breast Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Metastatic Breast Cancer - Pipeline Review, H2 2015’, provides an overview of the Metastatic Breast Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Metastatic Breast Cancer Overview
Therapeutics Development
Metastatic Breast Cancer - Therapeutics under Development by Companies
Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Breast Cancer - Pipeline Products Glance
Metastatic Breast Cancer - Products under Development by Companies
Metastatic Breast Cancer - Products under Investigation by Universities/Institutes
Metastatic Breast Cancer - Companies Involved in Therapeutics Development
Metastatic Breast Cancer - Therapeutics Assessment
Drug Profiles
Metastatic Breast Cancer - Recent Pipeline Updates
Metastatic Breast Cancer - Dormant Projects
Metastatic Breast Cancer - Discontinued Products
Metastatic Breast Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Metastatic Breast Cancer, H2 2015
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Investigation by Universities/Institutes, H2 2015
Metastatic Breast Cancer - Pipeline by AB Science SA, H2 2015
Metastatic Breast Cancer - Pipeline by AbbVie Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H2 2015
Metastatic Breast Cancer - Pipeline by Ambrx, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Amgen Inc., H2 2015
Metastatic Breast Cancer - Pipeline by AngioGenex, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Aphios Corporation, H2 2015
Metastatic Breast Cancer - Pipeline by arGEN-X BV, H2 2015
Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H2 2015
Metastatic Breast Cancer - Pipeline by Bayer AG, H2 2015
Metastatic Breast Cancer - Pipeline by BIOCAD, H2 2015
Metastatic Breast Cancer - Pipeline by Biocon Limited, H2 2015
Metastatic Breast Cancer - Pipeline by Bionovis SA, H2 2015
Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
Metastatic Breast Cancer - Pipeline by Campus Technologies Freiburg GmbH, H2 2015
Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Celgene Corporation, H2 2015
Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Clovis Oncology, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2015
Metastatic Breast Cancer - Pipeline by Curadis GmbH, H2 2015
Metastatic Breast Cancer - Pipeline by Curaxys, S.L., H2 2015
Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H2 2015
Metastatic Breast Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Metastatic Breast Cancer - Pipeline by EirGenix Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H2 2015
Metastatic Breast Cancer - Pipeline by Ensol Biosciences Inc., H2 2015
Metastatic Breast Cancer - Pipeline by EOS Biosciences, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Etubics Corporation, H2 2015
Metastatic Breast Cancer - Pipeline by Eureka Therapeutics, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Galileo Research s.r.l., H2 2015
Metastatic Breast Cancer - Pipeline by Genelux Corporation, H2 2015
Metastatic Breast Cancer - Pipeline by Genentech, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H2 2015
Metastatic Breast Cancer - Pipeline by GTx, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Hetero Drugs Limited, H2 2015
Metastatic Breast Cancer - Pipeline by Hospira, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Immune Design Corp., H2 2015
Metastatic Breast Cancer - Pipeline by Immunomedics, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Immupharma Plc, H2 2015
Metastatic Breast Cancer - Pipeline by Imugene Limited, H2 2015
Metastatic Breast Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Incyte Corporation, H2 2015
Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H2 2015
Metastatic Breast Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015
Metastatic Breast Cancer - Pipeline by Kancera AB, H2 2015
Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
Metastatic Breast Cancer - Pipeline by Mabion SA, H2 2015
Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by MandalMed, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Meabco A/S, H2 2015
Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H2 2015
Metastatic Breast Cancer - Pipeline by Medivation, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Merck & Co., Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Merck KGaA, H2 2015
Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Merus B.V., H2 2015
Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Morphotek, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Mycenax Biotech Inc., H2 2015
Metastatic Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by NantKwest, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H2 2015
Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H2 2015
Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H2 2015
Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Novartis AG, H2 2015
Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2015
Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Oncobiologics, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015
Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Oncothyreon Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2015
Metastatic Breast Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Pfizer Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H2 2015
Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Radius Health, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Samyang Holdings Corporation, H2 2015
Metastatic Breast Cancer - Pipeline by Sanofi, H2 2015
Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H2 2015
Metastatic Breast Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Metastatic Breast Cancer - Pipeline by Theracrine, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H2 2015
Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H2 2015
Metastatic Breast Cancer - Pipeline by Verastem, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Wilex AG, H2 2015
Metastatic Breast Cancer - Pipeline by WntResearch AB, H2 2015
Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Zymeworks Inc., H2 2015
Metastatic Breast Cancer - Pipeline by Zyngenia, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Metastatic Breast Cancer - Dormant Projects, H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..1), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..2), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..3), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..4), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..5), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..6), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..7), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..8), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..9), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..10), H2 2015
Metastatic Breast Cancer - Dormant Projects (Contd..11), H2 2015
Metastatic Breast Cancer - Discontinued Products, H2 2015
Metastatic Breast Cancer - Discontinued Products (Contd..1), H2 2015
Metastatic Breast Cancer - Discontinued Products (Contd..2), H2 2015
Metastatic Breast Cancer - Discontinued Products (Contd..3), H2 2015
Metastatic Breast Cancer - Discontinued Products (Contd..4), H2 2015

LIST OF FIGURES

Number of Products under Development for Metastatic Breast Cancer, H2 2015
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Advaxis, Inc.
Advenchen Laboratories, LLC
Amarna Therapeutics B.V.
Ambrx, Inc.
Amgen Inc.
AngioGenex, Inc.
Aphios Corporation
arGEN-X BV
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
BIOCAD
Biocon Limited
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Campus Technologies Freiburg GmbH
CASI Pharmaceuticals Inc.
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Celltrion, Inc.
Clovis Oncology, Inc.
Corcept Therapeutics Incorporated
Curadis GmbH
Curaxys, S.L.
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
Dompe Farmaceutici S.p.A.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Ensol Biosciences Inc.
EOS Biosciences, Inc.
Epirus Biopharmaceuticals, Inc.
Etubics Corporation
Eureka Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Galileo Research s.r.l.
Genelux Corporation
Genentech, Inc.
Genor BioPharma Co., Ltd.
Glycotope GmbH
GTx, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hetero Drugs Limited
Hospira, Inc.
Immune Design Corp.
Immunomedics, Inc.
Immupharma Plc
Imugene Limited
Inbiopro Solutions Pvt. Ltd.
Incyte Corporation
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kancera AB
Karyopharm Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Mabion SA
MacroGenics, Inc.
MandalMed, Inc.
Meabco A/S
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Merus B.V.
MetaStat, Inc.
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
Mycenax Biotech Inc.
NanoCarrier Co., Ltd.
NantKwest, Inc.
Natco Pharma Limited
Nektar Therapeutics
NewLink Genetics Corporation
Nippon Kayaku Co., Ltd.
Northwest Biotherapeutics, Inc.
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncobiologics, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Pharmaceuticals, Inc.
Paras Biopharmaceuticals Finland Oy
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharma Mar, S.A.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Polyphor Ltd.
Prima BioMed Ltd.
Puma Biotechnology, Inc.
Radius Health, Inc.
Samyang Holdings Corporation
Sanofi
Seattle Genetics, Inc.
Shanghai Henlius Biotech Co., Ltd.
Starpharma Holdings Limited
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Syndax Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Theracrine, Inc.
Transgene Biotek Limited
Vaxil Bio Therapeutics Ltd.
Verastem, Inc.
Vertex Pharmaceuticals Incorporated
VioQuest Pharmaceuticals, Inc.
Wilex AG
WntResearch AB
ZIOPHARM Oncology, Inc.
Zymeworks Inc.
Zyngenia, Inc.
Skip to top


Breast Cancer - Pipeline Review, H2 2015 US$ 2,125.00 Dec, 2015 · 2995 pages
Metastatic Liver Cancer - Pipeline Review, H2 2015 US$ 1,600.00 Oct, 2015 · 58 pages
Metastatic Pancreatic Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 416 pages

Ask Your Question

Metastatic Breast Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: